AOD-9604 and fat metabolism

The growth-hormone fragment

The attractive idea is separation: can a fragment of growth hormone retain a useful metabolic activity? Preclinical metabolic studies examined AOD-9604 as a synthetic lipolytic and antilipogenic domain of the hormone. The neatness appeals to me. A small component sounds easier to grasp than the whole machine.

But the early experiments become more interesting when the broad phrase “fat metabolism” is opened up. Making fat, releasing fat and oxidising fat are different jobs. The fragment’s history supplies reasons to be particular about which job an experiment measured.

Fat synthesis in rat tissue

An earlier study of the related synthetic hGH fragment 177–191 found antilipogenic activity in rat fat-pad preparations, while measuring no significant lipolytic effect through glycerol release. Antilipogenic means suppressing the making of fat. Lipolytic refers to breaking stored fat down.

This is where the shorthand becomes slippery. The preparation in that paper was a C-terminal sequence of growth hormone; its finding needs to stay attached to that fragment and that tissue assay. I resist treating every related fragment as interchangeable with AOD-9604.

That is why, to my ear, “fat burning” is such an unsatisfying description. It folds several possible actions into a phrase that sounds like a finished result. The rat-tissue experiment gives a narrower, more useful account of an activity that was actually measured.

Obese mice and receptor-knockout mice

The chronic-treatment experiment in obese mice and beta-3 receptor-knockout mice has a pleasingly direct question: which effects survive when a suspected part of the machinery is missing? A knockout mouse has been engineered to lack the relevant functional receptor.

After 14 days of chronic intraperitoneal treatment, both human growth hormone and AOD9604 reduced body weight and fat in obese mice and increased beta-3 adrenergic receptor RNA expression. In the knockout mice, the chronic weight and lipolytic response was abolished. Acute increases in energy expenditure and fat oxidation persisted.

The same experiment therefore separates the chronic response from the acute metabolic response. I’d pin that split between acute and chronic responses over the workbench. The receptor matters, yet removing it leaves some activity intact. A tidy account with a single on-off switch would have missed the distinction.

To me, the impressive feature is the experiment’s ability to make the mechanism less simple. The finding supports an account of these mice under these experimental conditions. Translating it into a claim of useful weight loss in people requires a human outcome that the mouse experiment cannot provide.

The oral human trials

The human evidence discussed here has a different centre of gravity. The safety and tolerability report covers roughly six clinical trials totalling about 900 obese subjects, with oral treatment durations from 7 days to 24 weeks. Across that programme, reported tolerability was indistinguishable from placebo, without the adverse effects associated with full-length growth hormone.

That tolerability observation deserves credit. Tolerability is a worthwhile outcome. It still answers a different question from whether someone lost a useful amount of weight because of the fragment. This report’s safety finding supplies no weight-loss result for me to celebrate here.

There is a route question as well. The human report concerns oral treatment, whereas the receptor experiment used intraperitoneal treatment in mice. These are distinct routes in distinct species. Turning that comparison into a practical human regimen would be guesswork.